ClinicalTrials.gg
Not yet recruitingNCT07240376ESSNARESUpdated Nov 20, 2025

Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome

An interventional study of Stapokibart (CM310) and Placebo in Non-Allergic Rhinitis With Eosinophilia Syndrome, sponsored by Huazhong University of Science and Technology. Not yet recruiting at 11 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Huazhong University of Science and Technology · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if Stapokibart (CM310) works to treat Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES) in adults. It will also learn about the safety of CM310.

The main questions it aims to answer are:

Does drug CM310 relieve the symptoms of participants? What medical problems do participants have when injecting CM310? Researchers will compare CM310 to a placebo (a look-alike substance that contains no drug) to see if CM310 works to treat NARES.

Participants will:

Inject CM310 or a placebo every 2 weeks for 12 weeks, and follow up for another 8 weeks.

Visit the clinic once every 2 weeks for checkups and tests. Keep a diary of their symptoms every day.

Read the detailed description

The objective of this clinical trial is to evaluate the efficacy of Stapokibart (CM310) in alleviating nasal and ocular symptoms, as well as its safety profile, in adult patients with Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES) who have shown a suboptimal response to intranasal corticosteroids.

Adult NARES patients with an inadequate response to mometasone furoate nasal spray will be enrolled. While continuing treatment with intranasal mometasone furoate, patients will be randomized to receive either Stapokibart or a placebo. Over the 12-week treatment period and the subsequent 8-week follow-up period, the alleviation of nasal and ocular symptoms, the incidence of adverse events, and the results of safety assessments (such as physical examinations, electrocardiograms, complete blood counts, and blood biochemistry) will be evaluated. The final aim is to assess the efficacy and safety of Stapokibart in treating patients with NARES.

02

Conditions studied

  • Non-Allergic Rhinitis With Eosinophilia Syndrome

Keywords

  • Stapokibart
  • Non-Allergic Rhinitis with Eosinophilia Syndrome
03

In context

Eosinophilia

52 studies on the registry are indexed under Eosinophilia; 9 are open to participants now.

This study's planned enrollment of 90 is above the median of 48 across 32 interventional studies indexed under Eosinophilia.

Browse Eosinophilia studies →

Lead sponsor

Huazhong University of Science and Technology is the lead sponsor of 248 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet all of the following criteria to be eligible for participation in this clinical trial.

    1. The subject must understand the nature of this study and must provide written , approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to undergoing any study-related procedures.
    2. Aged ≥18 and ≤65 years, regardless of gender.
    3. Diagnosed with Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES) according to the following criteria: chronic course lasting ≥2 years, with intermittent nasal symptoms including alternating nasal congestion, watery rhinorrhea, paroxysmal sneezing, nasal itching, postnasal drip, and hyposmia; with evidence against allergic rhinitis.
    4. Laboratory evidence: negative serum Specific Immunoglobulin E (sIgE) and negative Skin Prick Test (SPT); nasal secretion eosinophil proportion >20% (after excluding epithelial cells).
    5. The subject's history prior to the screening period indicates inadequate control of NARES symptoms (with an iTNSS ≥4 and at least one of the symptoms - nasal congestion, rhinorrhea, nasal itching, or sneezing - scoring ≥2) despite the use of intranasal or other medications (e.g., antihistamines, leukotriene receptor antagonists) following symptom onset.
    6. At the baseline visit (after run-in treatment), the subject must meet the following criteria: an iTNSS ≥4, the average of the most recent 6 daily Reflective Total Nasal Symptom Scores (rTNSS) ≥4, and at least one of the symptoms - nasal congestion, rhinorrhea, nasal itching, or sneezing - scoring ≥2 in these assessments (i.e., the 3 morning and 3 evening evaluations over the last three 24-hour periods, including the iTNSS assessment at the baseline visit).
    7. Willing and able to comply with all visits, study-related procedures, and questionnaires, including adherence to required background medications and completion of a daily electronic diary (eDiary). During the screening/run-in period, subjects must complete at least 80% of the diary assessments.
    8. Subjects agree to use highly effective (including vasectomy, abstinence, etc.) throughout the study period (from signing the ICF until 3 months after the last dose of study drug).

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following criteria are not eligible to participate in this clinical trial.

    1. History of allergy to study drugs: or intolerance to mometasone furoate, loratadine, CM310 injection, or any component of the placebo.
    2. Laboratory abnormalities: severe hepatic or renal dysfunction, abnormal liver function [ (ALT)/Aspartate Transaminase (AST) >1.5 × (ULN), or Total (TBIL) >1.5 × ULN with abnormal AST] or abnormal renal function (serum creatinine >1.2 × ULN); abnormalities in laboratory blood chemistry or hematology results at screening (Visit 1) or baseline (Visit 2) as judged by the investigator.
    3. History of harmful behavior: history of drug abuse, alcohol dependence (average daily alcohol intake >40 g) within 2 years prior to screening, or current drug user.
    4. Currently receiving allergen immunotherapy (subcutaneous or sublingual immunotherapy [SCIT/SLIT]). Subjects who discontinued SCIT/SLIT ≥3 years prior to randomization and are not on a maintenance regimen are eligible.
    5. Use of any rescue medication during the screening and run-in periods.
    6. Nasal procedure history at screening (Visit 1): nasal sinus surgery within 1 year prior to screening or presence of unhealed nasal trauma.
    7. Drug exposure at screening (Visit 1): participation in another drug clinical trial and use of an drug within 3 months prior to screening, or planned use of another investigational drug during the study.
    8. Vaccination at screening (Visit 1): receipt of a within 12 weeks prior to screening or planned vaccination with a live attenuated vaccine during the trial.
    9. Ocular disease at screening (Visit 1): presence of glaucoma, cataract, ocular herpes simplex, infectious conjunctivitis, or other ocular infections.
    10. Infection history at screening (Visit 1): active or inactive pulmonary tuberculosis infection; untreated localized or systemic fungal, bacterial, viral, or parasitic infection requiring ongoing treatment which, in the investigator's judgment, may place the subject at undue risk or affect result interpretation (e.g., severe infection requiring hospitalization and/or IV or equivalent oral antibiotics); symptomatic herpes zoster infection not resolved at screening; recurrent infections (including but not limited to recurrent cellulitis, chronic osteomyelitis). Subjects with only recurrent, mild, uncomplicated herpes labialis and/or genital herpes may be enrolled. Subjects with a history of active or latent tuberculosis with written evidence of adequate treatment, no history of re-exposure since completion of treatment, and no evidence of active tuberculosis on chest X-ray at screening may be enrolled.
    11. Subjects with comorbid asthma (including suspected asthma) are excluded if they meet any of the following: ≤60% of predicted; or an asthma exacerbation within 3 months prior to screening requiring systemic or hospitalization (>24 hours); or required inhaled corticosteroid dosage >1000 μg fluticasone propionate or equivalent.
    12. Known history of recurrent acute or chronic rhinosinusitis, defined as requiring systemic antibiotic treatment within 3 months prior to screening, or >4 recurrences within 2 years prior to screening.
    13. Conditions affecting drug deposition: nasal disease or symptoms/signs identified during screening or prior to randomization that, in the investigator's judgment, may affect intranasal drug deposition, such as acute or chronic sinusitis, symptoms/signs of chronic purulent postnasal drip, rhinitis medicamentosa, nasal polyps, vasomotor rhinitis, other clinically significant respiratory tract deformities/nasal structural abnormalities, significant nasal trauma (e.g., penetrating injury), or significant nasal septum deviation; any nasal mucosal erosion, nasal septum ulcer, or perforation at screening or prior to randomization; recent nasal piercing not fully healed that may cause nasal symptoms, or planned new nasal piercing during the study.
    14. Restricted medication use prior to run-in period: use of the following medications and/or treatments within a specified time prior to the run-in period or within 5 half-lives of the drug: IL-4Rα antagonists (within 10 weeks or 5 half-lives), vasoconstrictors (3 days), strong sedatives (3 days), antihistamines (10 days), decongestants (3 days), leukotriene receptor antagonists (7 days), anticholinergics (7 days), cromolyn-like drugs (14 days), systemic antibiotics (14 days), ocular mast cell stabilizers (14 days), monoamine oxidase inhibitors (14 days), tricyclic antidepressants (14 days), strong inducers/inhibitors (14 days), anti-allergy Chinese herbal medicines (14 days), short- or medium-acting systemic corticosteroids (4 weeks), long-acting systemic corticosteroids (6 weeks), immunotherapy such as desensitization therapy and other biologic monoclonal antibody therapies (3 months), etc.
    15. : treatment with biologics/systemic immunosuppressants (including but not limited to methotrexate, cyclosporine, mycophenolate mofetil, tacrolimus, penicillamine, sulfasalazine, hydroxychloroquine, azathioprine, cyclophosphamide) for inflammatory or diseases (e.g., rheumatoid arthritis, inflammatory bowel disease, primary biliary cholangitis, systemic lupus erythematosus, multiple sclerosis) within 8 weeks prior to randomization or within 5 half-lives (whichever is longer); known or suspected history of immunosuppression, including history of invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) even if resolved; or abnormally frequent, recurrent, or prolonged infections as judged by the investigator.
    16. Restricted medication use during the trial: planned use during the trial of the following drugs and/or treatments: a. strong CYP3A4 inducers/inhibitors; b. chronic or intermittent use of corticosteroids (except investigational product); c. antihistamines; d. leukotriene receptor antagonists; e. mast cell membrane stabilizers; f. systemic or intranasal decongestants; g. anticholinergics; h. immunosuppressants; i. anti-allergy Chinese herbal medicines/proprietary Chinese medicines/health products; j. anti-IgE antibodies (e.g., omalizumab for injection); k. nasal irrigations (including saline).
    17. Female subjects who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
    18. Presence of any other medical or psychological condition that, in the investigator's opinion, may indicate a new and/or insufficiently understood disease, participation in this clinical study may pose an unreasonable risk to the subject, may make the subject unable to participate stably in the study, or may interfere with study evaluations.
    19. Geographical restrictions: planned long-term travel away from the place of residence for ≥4 consecutive weeks during the trial, or planned residence in an area with a significantly different climate from the long-term place of residence.
    20. Previous participation in a CM310 clinical trial.
    21. Previous use of any anti-IL-4Rα monoclonal antibody (e.g., dupilumab) with inadequate treatment response (e.g., treatment failure or intolerance).
    22. Presence of other uncontrolled severe diseases or recurrent chronic comorbidities, including but not limited to active infection, cardiovascular and cerebrovascular diseases, tuberculosis or other pathogen infections, diabetes, autoimmune diseases, (HIV) infection, Treponema pallidum infection, active or C, or parasitic diseases.
    23. History of within 5 years prior to screening.
    24. Any other medical or non-medical condition that, in the investigator's opinion, makes the subject unsuitable for participation in this study
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    CM310 group

    After enrollment, paticipants were given CM310 (with an initial dose of 600 mg followed by 300mg subcutaneous injection, once every two weeks) for 12 weeks. Follow up for another 8 weeks.Mometasone furoate was nasal sprayed daily during treatment

    Biological: Stapokibart (CM310)

  • Placebo comparator
    Placebo group

    After enrollment, paticipants were given a placebo (subcutaneous injection, with the same dose as the experimental group, once every two weeks) for 12 weeks. Follow up for another 8 weeks. During the treatment period, mometasone furoate was sprayed nasal every day

    Other: Placebo

Interventions

  • BiologicalStapokibartStudies of StapokibartStapokibart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Paticipants were given CM310 (with an initial dose of 600 mg followed by 300mg subcutaneous injection, once every two weeks) for 12 weeks. Follow up for another 8 weeks.During the treatment period, mometasone furoate was sprayed nasal every day

  • OtherPlacebo

    After enrollment, paticipants were given a placebo (subcutaneous injection, with the same dose as the experimental group, once every two weeks) for 12 weeks. Follow up for another 8 weeks. During the treatment period, mometasone furoate was sprayed nasal every day

06

What researchers measure

Primary outcomes

  1. The mean change from baseline in the Reflective Total Nasal Symptom Score (rTNSS) at Week 12.

    The Reflective Total Nasal Symptom Score (rTNSS) assesses the severity of nasal symptoms over the past 12 hours and is evaluated in the morning (ante meridiem rTNSS, AMrTNSS) and evening (post meridiem rTNSS, PMrTNSS). The daily rTNSS is the average of AMrTNSS and PMrTNSS. rTNSS isa scoring scale ranging from 0 to 12, with higher scores indicating more severe symptoms.

    Time frame: From enrollment to the end of treatment at 12 weeks

Secondary outcomes

  1. reflective Total Nasal Symptom Scores

    Mean change from baseline in daily morning AM reflective Total Nasal Symptom Scores (AMrTNSS) during the treatment period; Mean change from baseline in daily evening PM reflective Total Nasal Symptom Scores (PMrTNSS) during the treatment period; rTNSS is the mean of AMrTNSS and PMrTNSS. The rTNSS, AMrTNSS, PMrTNSS are scoring scales ranging from 0 to 12, with higher scores indicating more severe symptoms

    Time frame: From enrollment to the end of study at 20 weeks

  2. Instant Total Nasal Symptom Score (iTNSS)

    Mean change from baseline in the Instant Total Nasal Symptom Score (iTNSS) immediately prior to dosing during the treatment period; The iTNSS is a scoring scale ranging from 0 to 12, with higher scores indicating more severe symptoms

    Time frame: From enrollment to the end of study at 20 weeks

  3. reflective individual nasal symptom scores

    Mean change from baseline in daily reflective individual nasal symptom scores (rhinorrhea, nasal congestion, nasal itching, sneezing) during the treatment period. Daily reflective individual nasal symptom scores are the means of daily daytime (AM) reflective individual nasal symptom scores and daily nighttime (PM) reflective individual nasal symptom scores. Each symptom score is a scale ranging from 0 to 3, with higher scores indicating more severe symptoms

    Time frame: From enrollment to the end of study at 20 weeks

  4. Reflective Total Ocular Symptom Score

    Mean change from baseline in the daily morning ante meridiem rTOSS (AMrTOSS) during the treatment period should be recorded; and mean change from baseline in the daily evening post meridiem rTOSS (PMrTOSS) during the treatment period should be recored; Mean change from baseline in the daily Reflective Total Ocular Symptom Score (rTOSS) during the treatment period should be calculated. Daily rTOSS is the mean of AMrTOSS and daily PMrTOSS. The rTOSS, AMrTOSS, PMrTOSS are scoring scales ranging from 0 to 9, with higher scores indicating more severe symptoms

    Time frame: From enrollment to the end of study at 20 weeks

  5. Instant Total Ocular Symptom Score (iTOSS)

    Mean change from baseline in the Instant Total Ocular Symptom Score (iTOSS) immediately prior to dosing during the treatment period. The rTOSS is a scoring scale ranging from 0 to 9, with higher scores indicating more severe symptoms

    Time frame: From enrollment to the end of study at 20 weeks

  6. reflective individual ocular symptom scores

    Mean change from baseline in daily reflective individual ocular symptom scores (ocular itching, tearing, eye redness) during the treatment period. Daily reflective individual ocular symptom scores are means of daytime (AM) reflective individual ocular symptom scores and nighttime (PM) reflective individual ocular symptom scores. Each of reflective individual ocular symptom score is a scale ranging from 0 to 3, with higher scores indicating more severe symptoms.

    Time frame: From enrollment to the end of study at 20 weeks

  7. Assessment of patient quality of life using the Rhino-Conjunctivitis Quality of Life Questionnaire (RQLQ)

    Assessment of patient quality of life using the Rhino-Conjunctivitis Quality of Life Questionnaire (RQLQ), including domains such as daily activities, sleep disturbance, practical problems, nasal symptoms, ocular symptoms, and emotional function, with calculation of the total score. The RQLQ is a scoring scale ranging from 0 to 168, with higher scores indicating a greater impact of symptoms on daily life.

    Time frame: From enrollment to the end of study at 20 weeks

  8. visual analogue scale of olfactory function

    Evaluation of olfactory function using the visual analogue scale (VAS).The VAS is a scoring scale ranging from 0 to 10, with higher scores indicating more severe symptoms.

    Time frame: From enrollment to the end of treatment at 12 weeks

  9. Overall evaluation of treatment response

    Overall evaluation of treatment response based on a 7-point categorical scale, where subjects rate the change in NARES symptoms at the end of the study as follows: significantly improved, moderately improved, mildly improved, no change, mildly worsened, moderately worsened, or significantly worsened.

    Time frame: From enrollment to the end of the study at 20 weeks

Other outcomes

  1. Area Under the Curve (AUC) for the change from baseline in daily rTNSS during the treatment period.

    Area Under the Curve (AUC) for the change from baseline in daily rTNSS during the treatment period.

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Number of days with no or mild symptoms during the treatment period.

    For daily rTNSS and rTOSS, days with no or mild symptoms are defined as follows: No or mild nasal symptoms: each individual symptom score (rhinorrhea, nasal congestion, nasal itching, sneezing) ≤ 1. No or mild ocular symptoms: each individual symptom score (ocular itching, tearing, eye redness) ≤ 1.

    Time frame: From enrollment to the end of treatment at 12 weeks

  3. Peripheral Blood eosinophil

    Peripheral Blood Parameters: Changes in eosinophil count will be recorded and Changes in eosinophil percentage will be calculated

    Time frame: At day 1, day 85 and day 141

  4. Peripheral Blood Cytokines and chemokines

    Peripheral Blood Cytokines and chemokines will be detected: Interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17A, Tumor Necrosis Factor (TNF)-α, Interferon (IFN)-γ, Monocyte Chemoattractant Protein (MCP)-1, Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Eosinophil Cationic Protein (ECP). The levels of peripheral blood cytokines and chemokines will be represented in picogram/milligram or nanogram/milligram

    Time frame: At day 1, day 85 and day 141

  5. Peripheral Blood Immunoglobulins

    Concentrations of specific and total Immunoglobulin (Ig) A, IgG4, IgG, IgE, and total IgM will be detected and represented in picogram/milligram or nanogram/milligram

    Time frame: At day 1, day 85 and day 141

  6. Nasal Secretion Neurotransmitters and Proteases

    Nasal secretion neurotransmitters and proteases: Vasoactive Intestinal Polypeptide (VIP), Substance P, histamine, 5-Hydroxytryptamine (5-HT), tryptase will be detected.The levels of neurotransmitters and proteases will be represented in picogram/milligram or nanogram/milligram

    Time frame: At day 1, day 85 and day 141

  7. Nasal Secretion Cytokines and chemokines

    Nasal Secretion cytokines and chemokines:IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17A, TNF-α, IFN-γ, MCP-1, G-CSF, GM-CSF, ECP, Charcot-Leyden Crystal (CLC), eotaxin-1, eotaxin-2 will be detected. The levels of nasal secretion cytokines and chemokines will be represented in picogram/milligram or nanogram/milligram

    Time frame: At day 1, day 85 and day 141

  8. Nasal Brush Cytology

    Nasal brush cytology: changes in eosinophil count will be recorded and changes in eosinophil percentage will be calculated.

    Time frame: At day 1, day 85 and day 141

  9. mRNA expression levels of genes of nasal brush cells

    The mRNA expression levels of CLC, Arachidonate 15-Lipoxygenase (ALOX15), ALOX5, Cyclooxygenase (COX), Transient Receptor Potential Melastatin 8 (TRPM8), Transient Receptor Potential Vanilloid subfamily 1 (TRPV1), TRPV4, and Transient Receptor Potential Ankyrin subtype 1 protein (TRPA1) will be detected.

    Time frame: At day 1, day 85 and day 141

  10. Safety Endpoints

    Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) will be reported

    Time frame: From enrollment to the end of study at 20 weeks

  11. Safty endpoint

    Abnormalities in physical examinations

    Time frame: From enrollment to the end of study at 20 weeks

  12. Safty endpoint

    Abnormalities in 12-lead electrocardiogram (ECG) will be reported

    Time frame: From enrollment to the end of study at 20 weeks

  13. Safty endpoint

    Abnormalities in complete blood count, blood chemistry, urinalysis will be reported.

    Time frame: From enrollment to the end of study at 20 weeks

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: Yes — IPD used in the results publication

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 6 months and ending 3 years after the publication of results

Access criteria: The study protocol, statistical analysis plan, and study results from this research will be available on ClinicalTrials.gov and in journals where the primary results are published. If additional data is required by other researchers, they may contact the corresponding author to request access to the data after the publication of the primary study findings.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Dec 2026, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Nov 20, 2025
StartEst.
Nov 25, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Feb 28, 2027
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07240376
Collaborators
Renmin Hospital of Wuhan University, Wuhan TongJi Hospital
Responsible party
Zheng Liu (M.D., Ph.D., FAAAAI Vice President, Chinese Society of Allergy Professor of Otolaryngology-Head & Neck Surgery Party Secretary of Zhongnan Hospital Wuhan University, Zhongnan Hospital) — Principal investigator
First posted
Nov 20, 2025
Start date
Nov 25, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 20, 2025

Study contacts

Yingxing Wu, Doctor
Contact
yingxing1006@126.com
+8613429856579
Ming Zeng, Doctor
Contact
zmsx77@163.com
+8618627006566
Zheng Liu
principal investigator · Zhongnan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion